Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
What the KRYSTAL-12 Lancet Correspondence Actually Says About PRO Reporting in KRASG12C Trials
1+ hour, 58+ min ago (233+ words) “Smit and Dingemans note that, although an in-depth analysis of quality-of-life measures was not provided in the primary publication, EQ-5D-5L scores appeared similar between treatment groups despite higher gastrointestinal toxicity with adagrasib.” “We thank Egbert F Smit and Anne-Marie C…...
Mabwell’s Bulumtatug Fuvedotin Shows Promise in Topo I-Pretreated TNBC
1+ mon, 2+ day ago (387+ words) The Clinical Trial Vanguard Mabwell’s Bulumtatug Fuvedotin Shows Promise in Topo I-Pretreated TNBC The clinical logic behind Mabwell’s ESMO oral slot is sharper than the announcement suggests: the Phase 2 study of bulumtatug fuvedotin (9MW2821) specifically enrolled patients with locally advanced or…...
What the MASAI Trial Correspondence in The Lancet Actually Says About AI Screening Evidence
1+ mon, 3+ week ago (805+ words) The Clinical Trial Vanguard What the MASAI Trial Correspondence in The Lancet Actually Says About AI Screening Evidence On June 28, 2026, The Lancet published a correspondence letter responding to the MASAI trial’s conclusions on AI-supported mammography screening. The letter deserves careful…...
FDA Accepts NDA for Roche’s Giredestrant in Early-Stage Breast Cancer
2+ mon, 2+ week ago (425+ words) The Clinical Trial Vanguard FDA Accepts NDA for Roche’s Giredestrant in Early-Stage Breast Cancer A 30% reduction in invasive disease recurrence or death — hazard ratio 0.70, p=0.0014 — is the number that earned giredestrant priority review, and it reframes what adjuvant endocrine therapy…...